Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × morphine, naltrexone combination × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Substance Withdrawal Syndrome 1 Chronic Pain 1

Interventions

Zoledronic Acid 18 Bevacizumab 12 nilotinib 11 Docetaxel 11 Everolimus 10 Letrozole 9 Imatinib Mesylate 9 Erlotinib Hydrochloride 9 Drug Therapy 9 Capecitabine 9 pegfilgrastim 8 enzalutamide 8 Paclitaxel 8 icotinib 6 Trastuzumab 6 Rituximab 6 Prednisone 6 Oxycodone 6 Nivolumab 6 Imiquimod 6 Gemcitabine 6 Epoetin Alfa 6 Diclofenac 6 Cisplatin 6 Carboplatin 6 Anastrozole 6 exemestane 5 epoetin beta 5 Oxaliplatin 5 Leuprolide 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01100437 2012-07-13

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Pfizer

Phase 4 Terminated

14 enrolled 18 charts

Substance Withdrawal Syndrome, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡